First‐Trimester Hematologic Inflammatory Markers and Pregnancy Loss in Women With Unexplained Recurrent Pregnancy Loss: A Retrospective Study of Associations and Discrimination
- 1Department of Reproductive Medicine Lanzhou University Second Hospital Lanzhou China
- 2Department of Obstetrics and Gynecology The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology Luoyang China
Abstract
Objective: This study aims to investigate whether complete blood count (CBC)‐derived systemic inflammation indices are associated with pregnancy loss in women with unexplained recurrent pregnancy loss (URPL).
Methods: This retrospective observational study included 517 women with URPL who were recruited from Lanzhou University Second Hospital between September 2019 and December 2022. Participants were categorized into the pregnancy loss (n = 265) group and live birth (n = 252) group. CBCs obtained at 4–8 weeks of gestation were used to calculate the neutrophil‐to‐lymphocyte ratio (NLR), monocyte‐to‐lymphocyte ratio (MLR), platelet‐to‐lymphocyte ratio (PLR), systemic immune‐inflammation index (SII), and systemic inflammation response index (SIRI). We fitted multivariable logistic regression models adjusted for age, education, ethnicity, and body mass index. We assessed in‐sample discriminative performance using receiver operating characteristic (ROC) curves.
Results: Compared with the live birth group, the pregnancy loss group had higher neutrophil counts, NLR, SII, SIRI, MLR, and PLR, and lower lymphocyte counts (all p < 0.001). After adjustment, higher NLR (OR = 3.05, 95% CI: 2.25–4.21), SIRI (OR = 2.74, 95% CI: 1.77–4.33), and SII (per 100‐unit increase, OR = 1.36, 95% CI: 1.24–1.51) were associated with greater odds of pregnancy loss. In tertile analyses, compared with the lowest tertile, the highest tertile was associated with higher odds of pregnancy loss for NLR (OR = 5.51), SII (OR = 2.88), SIRI (OR = 2.55), MLR (OR = 2.41), and PLR (OR = 3.41), with all p‐values for trend < 0.001. In ROC analyses, NLR showed the highest in‐sample discriminative performance (AUC = 0.752), followed by SII (AUC = 0.716).
Conclusion: First‐trimester CBC‐derived inflammatory indices, particularly NLR and SII, were associated with pregnancy loss in women with URPL and may have potential discriminative value within this cohort. These findings require confirmation in prospective, multicenter studies with broader confounder assessment and external validation before any clinical application can be considered.
Related
- Therapeutic role of granulocyte-colony stimulating factor and aspirin in unexplained recurrent pregnancy loss: a retrospective study.
- Characteristics of serum Metrnl levels in patients with neuromyelitis optica spectrum disorder and their associations with disease activity and inflammatory biomarkers
- Associations between redox-related biomarkers and treatment response in patients with inflammatory bowel disease initiating infliximab or vedolizumab
- Acne therapy with isotretinoin is well tolerated in patients with established inflammatory bowel disease: a retrospective, single center study.
- Risk factors and prediction model of renal dysfunction in patients with inflammatory bowel disease: a retrospective cohort study.
BibTeX
@article{wang2026firsttrimester,
title = {{First‐Trimester Hematologic Inflammatory Markers and Pregnancy Loss in Women With Unexplained Recurrent Pregnancy Loss: A Retrospective Study of Associations and Discrimination}},
author = {Ruifang Wang and Fangxiang Mu and Wei Zhang and Kexin Wang and Fang Wang},
journal = {Immunity, Inflammation and Disease},
year = {2026},
month = nov,
doi = {10.1002/iid3.70535},
url = {https://doi.org/10.1002/iid3.70535},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - First‐Trimester Hematologic Inflammatory Markers and Pregnancy Loss in Women With Unexplained Recurrent Pregnancy Loss: A Retrospective Study of Associations and Discrimination
AU - Ruifang Wang
AU - Fangxiang Mu
AU - Wei Zhang
AU - Kexin Wang
AU - Fang Wang
PY - 2026
DA - 2026/11/05
JO - Immunity, Inflammation and Disease
DO - 10.1002/iid3.70535
UR - https://doi.org/10.1002/iid3.70535
AB - Objective: This study aims to investigate whether complete blood count (CBC)‐derived systemic inflammation indices are associated with pregnancy loss in women with unexplained recurrent pregnancy loss (URPL). Methods: This retrospective observational study included 517 women with URPL who were recruited from Lanzhou University Second Hospital between September 2019 and December 2022. Participants were categorized into the pregnancy loss (n = 265) group and live birth (n = 252) group. CBCs obtained at 4–8 weeks of gestation were used to calculate the neutrophil‐to‐lymphocyte ratio (NLR), monocyte‐to‐lymphocyte ratio (MLR), platelet‐to‐lymphocyte ratio (PLR), systemic immune‐inflammation index (SII), and systemic inflammation response index (SIRI). We fitted multivariable logistic regression models adjusted for age, education, ethnicity, and body mass index. We assessed in‐sample discriminative performance using receiver operating characteristic (ROC) curves. Results: Compared with the live birth group, the pregnancy loss group had higher neutrophil counts, NLR, SII, SIRI, MLR, and PLR, and lower lymphocyte counts (all p < 0.001). After adjustment, higher NLR (OR = 3.05, 95% CI: 2.25–4.21), SIRI (OR = 2.74, 95% CI: 1.77–4.33), and SII (per 100‐unit increase, OR = 1.36, 95% CI: 1.24–1.51) were associated with greater odds of pregnancy loss. In tertile analyses, compared with the lowest tertile, the highest tertile was associated with higher odds of pregnancy loss for NLR (OR = 5.51), SII (OR = 2.88), SIRI (OR = 2.55), MLR (OR = 2.41), and PLR (OR = 3.41), with all p‐values for trend < 0.001. In ROC analyses, NLR showed the highest in‐sample discriminative performance (AUC = 0.752), followed by SII (AUC = 0.716). Conclusion: First‐trimester CBC‐derived inflammatory indices, particularly NLR and SII, were associated with pregnancy loss in women with URPL and may have potential discriminative value within this cohort. These findings require confirmation in prospective, multicenter studies with broader confounder assessment and external validation before any clinical application can be considered.
SN - 2050-4527
ER -